epidemic

1 stories · following the connections

Business

Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV

By Nasdaq OMXSep 9, 2016, 10:15 AM UTC